Close
Almac
Achema middle east

Thermo Fisher Scientific Completes MarqMetrix Acquisition

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.
- Advertisement -

Thermo Fisher Scientific Inc. has completed its acquisition of MarqMetrix, a privately held developer of Raman-based spectroscopy solutions for in-line measurement. The terms of the deal were not disclosed.

Based in Seattle, WA, MarqMetrix provides innovative and fit-for-purpose in-line Process Analytical Technology (PAT), offering customers a simplified method to make precise and accurate measurements throughout the manufacturing process for a wide range of applications, including biopharma and pharmaceuticals, oil and gas, and chemicals and polymers.

MarqMetrix has approximately 30 employees based in the U.S. MarqMetrix will become part of Thermo Fisher’s Analytical Instruments segment.

“The acquisition of MarqMetrix is an excellent strategic fit for Thermo Fisher and adds highly complementary Raman-based in-line PAT to Thermo Fisher’s portfolio,” said Miguel Faustino, President, Chemical Analysis, Thermo Fisher. “MarqMetrix will add expanded and differentiated capabilities to Thermo Fisher’s leading portfolio of analytical solutions to address customer requirements for real-time measurement and process control of critical manufacturing process parameters that affect quality. We look forward to welcoming the MarqMetrix team to Thermo Fisher.”

Latest stories

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »